Engineering CAR T cells for enhanced efficacy and safety
Despite its success in treating hematologic malignancies, chimeric antigen receptor (CAR) T cell therapy faces two major challenges which hinder its broader applications: the limited effectiveness against solid tumors and the nonspecific toxicities. To address these concerns, researchers have used s...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AIP Publishing LLC
2022-03-01
|
| Series: | APL Bioengineering |
| Online Access: | http://dx.doi.org/10.1063/5.0073746 |